
Opinion|Videos|March 13, 2025
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
Author(s)Matthew Galsky, MD
An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after surgery. It enrolled 709 patients, assessing disease-free survival and overall survival as primary end points.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please provide an overview of the CheckMate 274 clinical trial (eg, design and population enrolled).
Advertisement
Related to this article

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5
